Core Insights - The article discusses a recent investigation by a well-known private equity firm, Hosheng Asset, into a listed company, Haoyuan Pharmaceutical, highlighting its competitive advantages and growth prospects [1] Company Overview - Haoyuan Pharmaceutical has high barriers to entry in its molecular building block business, with a diverse range of products and strong custom R&D capabilities [1] - The company is projected to achieve a revenue of 420 million yuan in 2024, representing a year-on-year growth of 35.7% [1] - Haoyuan's CDMO (Contract Development and Manufacturing Organization) business covers the entire drug development and production process, showcasing core technological, product, and team advantages [1] Production Capabilities - The company has established a production system comprising four key facilities: an API (Active Pharmaceutical Ingredient) factory, a formulation factory, a high-end intermediate factory, and a DC CDMO factory, enabling a three-tiered capacity arrangement [1] - Haoyuan has passed the EU QP audit, ensuring its quality management system and production capabilities meet EU GMP standards, which facilitates further expansion into domestic and international markets [1] Team and Incentives - The company has implemented multiple equity incentive plans targeting core personnel and mid-to-senior management to ensure team stability and creativity [1] Financial Activities - On November 28, 2024, Haoyuan successfully issued convertible bonds, raising 822 million yuan, although it has not yet met the conditions for strong redemption [1]

Group 1 - The company plans to dispose of up to 3 million shares of Beijing Beilu Pharmaceutical Co., Ltd. through Shenzhen Stock Exchange within three months after the pre-disclosure announcement of the reduction plan [1][2] - The company has completed the disposal of 2,998,800 shares of Beilu Pharmaceutical from March 24, 2025, to June 19, 2025, at an average transaction price of 7.46 yuan per share, totaling a transaction amount of 22,364,330 yuan [1][2] Group 2 - After the disposal, the company still holds 37,465,700 shares of Beilu Pharmaceutical, which represents a significant portion of its holdings [2] - The transaction is expected to enhance the company's asset liquidity and efficiency, allowing it to focus resources on core business development, with an estimated net profit increase of approximately 12.25 million yuan after deducting costs and related transaction taxes [2]

湖北山河律师事务所 Hubei S&H Law Firm 人福医药集团股份公司 法律意见书 （2025）山河非章第 2344 号 ：2025 年 6 月 20 日 时间（Date） 致：人福医药集团股份公司 根据《中华人民共和国公司法》（以下简称"《公司法》"） 、《中华人民 共和国证券法》 （以下简称"《证券法》"）、 《上市公司股东会规则》 （以下简 称"《股东会规则》"）以及《人福医药集团股份公司章程》 （以下简称"《公 司章程》"）、 《人福医药集团股份公司股东大会议事规则》 （以下简称" 《股 东大会议事规则》 "）等内部规章制度的有关规定，湖北山河律师事务所（以 下简称"本所"）接受人福医药集团股份公司（以下简称"人福医药"或"公司" ） 的委托，指派本所执业律师（以下简称"本所律师"）出席人福医药 2024 年 年度股东会（以下简称"本次股东会"）并出具法律意见。 为出具本法律意见书，本所律师出席了本次股东会，审查了公司提供 的有关本次股东会的相关文件，听取了公司董事会及监事会就有关事项所 作的说明。本所已得到人福医药的如下保证：人福医药已向本所提供了出 具法律意见书所必需的、真实的原始书面材料 ...

证券代码：603538 证券简称：美诺华 公告编号：2025-078 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于权益分派引起的"美诺转债"转股价格调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许可20202377 号）核准，2021 年 1 月 14 日， 宁波美诺华药业股份有限公司（以下简称"公司"）公开发行 52,000 万元可转换 公司债券，共发行 520 万张，每张面值 100 元，期限 6 年。2021 年 2 月 4 日起， 上述可转换公司债券在上海证券交易所挂牌交易，转债简称"美诺转债"，转债代 码"113618"。 "美诺转债"存续的起止日期为 2021 年 1 月 14 日至 2027 年 1 月 13 日，转 股期起止日期为 2021 年 7 月 20 日至 2027 年 1 月 13 日，初始转股价格为 37.47 元/股。 ? 证券停复牌情况： ...

Key Points - The company announced a cash dividend of 0.112 CNY per share for A shares [1] - The total cash dividend distribution amounts to approximately 100.65 million CNY based on a total share capital of 898,669,632 shares [1] - The dividend distribution plan was approved at the annual shareholders' meeting held on April 29, 2025 [1] - Key dates for the dividend distribution include the record date on June 26, 2025, and the ex-dividend date on June 27, 2025 [1][2] - The company will distribute dividends through China Securities Depository and Clearing Corporation Limited Shanghai Branch [1] - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax [3] - For individual shareholders holding shares for less than one year, the tax will be calculated upon the transfer of shares [3] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax on dividends, resulting in a net dividend of 0.1008 CNY per share [4][5] - The company will not withhold corporate income tax for other institutional investors, allowing them to determine their tax obligations independently [5]

江苏联环药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?每股分配比例 A 股每股现金红利0.089元 证券代码：600513 证券简称：联环药业 公告编号：2025-037 ?相关日期 股份类别 股权登记日 最后交易日 除权（息）日 现金红利发放日 Ａ股 2025/6/20 － 2025/6/23 2025/6/23 ?差异化分红送转：否 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 9 日的2024年年度股东会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 三、相关日期 股份类别 股权登记日 最后交易日 除权（息）日 现金红利发放日 Ａ股 2025/6/20 － 2025/6/23 2025/6/23 四、分配实施办法 （1）无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统 向股权登记日上海证券交易所收市后登记在册并在上海 ...

常山药业：艾本那肽注射液用于减重适应症的临床试验申请获得批准 智通财经6月20日电，常山药业(300255.SZ)公告称，常山药业及控股子公司常山凯捷健近日收到国家药 品监督管理局核准签发的《药物临床试验批准通知书》，艾本那肽注射液用于减重适应症的临床试验申 请获得批准。艾本那肽是一种长效胰高血糖素样肽-1受体激动剂，通过激活GLP-1受体以葡萄糖浓度依 赖的方式刺激胰岛素分泌和抑制胰高糖素分泌，同时增加肌肉和脂肪组织葡萄糖摄取，抑制肝脏葡萄糖 的生成而发挥降糖作用。根据药品注册相关的法律法规要求，药物在获得临床试验批准通知书后，尚需 完成后续临床试验并经国家药品监督管理局审评、审批通过后方可上市。本次获取临床试验批准通知书 不会对公司近期业绩产生重大影响。药品在取得临床试验许可后，尚需开展临床试验，临床研究受到多 种不确定因素影响，存在结果不及预期甚至临床研究失败的风险。药品研发存在投入大、周期长、风险 高等特点，药物从临床试验到投产上市会受到技术、审批、政策等多方面因素的影响，临床试验进度及 结果、未来产品市场竞争形势均存在诸多不确定性。 ...

Market Overview - The FTSE China A50 Index components showed a mixed performance with the banking and insurance sectors continuing to rise in the afternoon, while the consumer electronics sector experienced divergent trends [1][7]. Banking and Insurance Sector - Major banks and insurance companies such as China Pacific Insurance, Ping An Insurance, and China Life Insurance reported market capitalizations of 376.78 billion, 340.36 billion, and 996.83 billion respectively, with trading volumes of 7.95 million, 46.06 million, and 6.95 million [3]. - The insurance sector saw positive changes with Ping An Insurance increasing by 1.54 (+2.89%) and China Life Insurance by 0.14 (+1.67%) [3]. Consumer Electronics Sector - The consumer electronics sector displayed mixed results, with companies like Industrial Fulian and Luxshare Precision reporting market capitalizations of 408.89 billion and 240.74 billion respectively, and trading volumes of 39.50 million and 10.37 million [4]. - Industrial Fulian's stock decreased by 0.22 (-1.06%), while Luxshare Precision increased by 0.18 (+0.35%) [4]. Alcohol Industry - The alcohol sector, represented by Kweichow Moutai and Wuliangye, showed strong market capitalizations of 1,794.68 billion and 223.79 billion respectively, with trading volumes of 49.91 million and 21.95 million [3]. - Kweichow Moutai's stock increased by 2.66 (+0.19%), while Wuliangye rose by 6.84 (+3.87%) [3]. Semiconductor Sector - The semiconductor industry, including companies like North Huachuang and Cambrian, reported market capitalizations of 227.97 billion and 310.30 billion respectively, with trading volumes of 14.35 million and 21.38 million [3]. - North Huachuang's stock increased by 3.21 (+0.76%), while Cambrian's stock decreased by 8.11 (-1.39%) [3]. Automotive Sector - The automotive sector, featuring Great Wall Motors and BYD, had market capitalizations of 179.31 billion and 1,869.56 billion respectively, with trading volumes of 25.08 million and 3.83 million [3]. - Great Wall Motors' stock decreased by 0.25 (-0.07%), while BYD's stock decreased by 0.16 (-0.76%) [3]. Energy Sector - The energy sector, including China Petroleum and China Shenhua, reported market capitalizations of 1,676.47 billion and 1,095.42 billion respectively, with trading volumes of 12.62 million and 8.75 million [3]. - China Petroleum's stock increased by 0.21 (+1.30%), while China Shenhua's stock decreased by 1.84 (-0.76%) [3].

Group 1: Market Overview - The FTSE China A50 Index components showed a rebound in banking, insurance, and liquor sectors, while the power sector continued to adjust [1][4][5] - Major insurance companies like China Pacific Insurance, China Life Insurance, and Ping An Insurance reported market capitalizations of 378.55 billion, 342.10 billion, and 994.83 billion respectively, with trading volumes of 4.88 million, 24.23 million, and 3.99 million [4] - The liquor industry, led by Kweichow Moutai, Wuliangye, and Shanxi Fenjiu, had market capitalizations of 1807.87 billion, 225.39 billion, and 463.74 billion respectively, with trading volumes of 27.96 million, 15.85 million, and 20.97 million [4] Group 2: Sector Performance - The semiconductor sector, including companies like Northern Huachuang and Cambrian, had market capitalizations of 226.75 billion and 240.86 billion respectively, with trading volumes of 7.87 million and 14.31 million [4] - In the automotive sector, Great Wall Motors and BYD reported market capitalizations of 281.32 billion and 1874.12 billion respectively, with trading volumes of 13.90 million and 1.60 million [4] - The power sector, represented by companies like Yangtze Power and China Nuclear Power, had market capitalizations of 746.53 billion and 329.67 billion respectively, with trading volumes of 9.73 million and 16.36 million [5] Group 3: Notable Companies - China Shenhua Energy and Shaanxi Coal and Chemical Industry had market capitalizations of 193.12 billion and 1095.10 billion respectively, with trading volumes of 4.57 million and 18.81 million [4] - In the food and beverage sector, companies like Citic Securities and Haitai Flavor reported market capitalizations of 385.04 billion and 325.62 billion respectively, with trading volumes of 5.48 million and 3.31 million [5] - The electronics sector, including companies like Industrial Fulian and Luxshare Precision, had market capitalizations of 342.13 billion and 409.89 billion respectively, with trading volumes of 5.39 million and 23.98 million [5]

Core Viewpoint - Multiple companies have announced significant developments, including investments, clarifications on business operations, and changes in control, which may present various investment opportunities and risks for stakeholders [2]. Company Announcements - **Hai Zheng Pharmaceutical** plans to establish a joint venture in synthetic biology with a registered capital of 350 million yuan, where Hai Zheng will contribute 260 million yuan, holding a 74.29% stake [3]. - **Jin Zhong Zi Jiu** clarified that its business scope remains unchanged despite media reports suggesting a shift away from liquor production, confirming that it will continue to focus on its core liquor business [4]. - **ST Gong Zhi** announced that its stock will resume trading on June 20, 2025, and enter a delisting period, with the last trading date expected to be July 10, 2025 [5]. - **Zhong Jing Electronics** confirmed that its production and operational conditions are normal, with no undisclosed significant matters [6]. - **Shan Jin International** is preparing for an overseas H-share issuance and listing on the Hong Kong Stock Exchange to enhance its global strategy [7]. - **Kang Da New Materials** intends to acquire at least 51% of Chengdu Zhongke Huamei Electronics to expand into the semiconductor integrated circuit sector [8]. - **Zhong Yan Chemical** agreed to a capital reduction for its subsidiary, which will result in it holding 100% of the subsidiary's equity, constituting a significant asset restructuring [9]. - **Tai Ji Co., Ltd.** announced a change in its actual controller to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading [10]. - **ST Yi Guo** plans to sell four Carrefour subsidiaries for 1 yuan, expecting to increase its net profit by approximately 572 million yuan, while focusing on its core home appliance business [11][12]. Performance Expectations - **Sheng Nuo Bio** anticipates a substantial increase in net profit for the first half of 2025, projecting a year-on-year growth of 253.54% to 332.10%, driven by strong performance in its peptide raw material business [13]. Share Buyback - **Nuo Wei Zan** intends to repurchase shares worth between 5 million and 10 million yuan to implement employee stock ownership plans, with a maximum repurchase price of 30 yuan per share [14]. Major Contracts - **Sai Sheng Pharmaceutical** signed a technology transfer contract for a new drug project with a total transaction amount of 20 million yuan, which will enhance its capabilities in the protein/antibody drug platform [15].